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RESULTS: Final analysis included 9337 patients. Mean age of patients was 41.75 
10.11 years. Sixty nine percent patients were males. Treatment success rate was
77.5% (n  7240). Among 7240 successfully treated patients, 5319 patients cured
while 1921 completed their treatment. Among 22.5% (n2097) unsuccessfully
treated patients, 503 died, 502 defaulted, 369 transferred out and 723 were on
treatment continued. In multivariate analysis new TB infection (OR1.315,
p-value0.001) was the only factor associated with successful treatment outcome.
Whereas extra pulmonary TB (OR0.541, p-value0.001), pulmonary  extra pul-
monary TB (O 0.523, p-value0.001), urban area (OR0.889, p-value0.030),
smoking (OR0.890, p-value0.030), alcohol consumption (OR0.807,
p-value0.011) intravenous drug use (OR0.676, p-value0.001) and employment
(OR0.507, p-value0.001) had statistically significant negative association with
successful treatment outcome. CONCLUSIONS: Although more than three fourth
(77.5%) patients were treated successfully but the treatment success rate is still
behind the WHO target of 85%. In future more attention should be paid to patients
with extra pulmonary TB, belonging to urban area, smokers, alcohol consumers,
intravenous drug users and employees.
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OBJECTIVES: An unmet need remains for new effective treatments and/or man-
agement strategies for influenza in high-risk groups. Complications and mortality
rates might differ among high risk groups, such as those who are aged 65 years and
older compared with those with different chronic underlying medical conditions.
METHODS: A literature review was performed using electronic database keyword
searches, specific inclusion and exclusion criteria, quality rating of the reviewed
full-text articles, and abstraction of data to evaluate the published evidence on the
incidence, complication rates, and health service use associated with clinical in-
fluenza in different high-risk groups. RESULTS: Key findings for incidence rates of
clinical influenza were that these rates are similar among people with chronic
cardiovascular or respiratory comorbidity but may be higher in those with alloge-
neic stem cell transplants compared to those with autologous transplants. Rates of
hospitalization and/or pneumonia or lower respiratory tract infection for those
with chronic conditions or those who are immunocompromised (2.9% to 80%) are
significantly higher than those in people over age 65 but without additional high-
risk factors (0%). A person who is hospitalized and has a laboratory-confirmed
influenza diagnosis has a probability of intensive care unit admission of between
11.8% and 28.6% and of death of between 2.9% and 14.3%. Most of the studies of
hospitalized patients did not present outcomes data separately by high-risk group.
In addition, the rates and outcomes of influenza complications in all high-risk
groups are variable from year to year depending on the circulating influenza
viruses. CONCLUSIONS: These findings indicate that the burden of influenza may
vary by high-risk group although there are only limited data available to quantify
these differences. This information could be used to evaluate new therapies, in-
cluding better influenza vaccines, chemoprophylaxis, and/or treatment strategies
for different high-risk groups.
INFECTION – Cost Studies
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VACCINE (PPV23) COMPARED TO NO VACCINATION (NOVAC) OR 13-VALENT
PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN THE UK
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OBJECTIVES: In the UK, PPV23 has been recommended in the elderly (aged 65 and
over) and at-risk adults. In 2007, PCV was introduced in children, leading to a
decrease in invasive pneumococcal disease (IPD) incidence associated with the PCV
serotypes not only in vaccinated children but also in unvaccinated adults. The use
of PCV13 in adults is currently under consideration pending data on efficacy in this
population. This study aimed to assess the BI of PPV23 vs. NoVac or PCV13 in the
UK, accounting for recent epidemiological changes. METHODS: The model was
adapted from a previous population-based Markov model, consisting of five health
states: no PD, IPD, NBPP (non-bacteraemic pneumococcal pneumonia), post-men-
ingitis sequelae and death. Epidemiology and costs were estimated from UK
sources. The analysis tracked cohorts of vaccinated and unvaccinated population
between 2012 and 2016. Four scenarios were tested and equal market shares were
assumed between PCV13 and PPV23. RESULTS: Over the study period, PPV23 vac-
cination led to a reduction in the number of IPD cases, ranging from 1,773 to 1,957
(vs. NoVac) or from -154 to 617 (vs. PCV13). The reduction in the number of NBPP
cases ranged from -2 to 23,969 (vs. NoVac) or from -11,984 to 0 (vs. PCV13). When
compared to NoVac, PPV23 vaccination was associated with a total cost of £63
million, whereas introducing PCV13 required an additional funds of £54 million.
The net budget impact ranged between £36 million and £59 million (vs. NoVac) or
between -£56 million and -£47 million (vs. PCV13). CONCLUSIONS: The model sug-
gests that vaccinating with PPV23 significantly reduces the burden of pneumococ-
cal disease despite the epidemiological changes. Introducing PCV13 is likely to
impose a significant impact on the health care budget and assumptions around the
efficacy of PCV13 are a substantial source of uncertainty in its public health bene-
fits.
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OBJECTIVES: The gradual increase of persons living with HIV, mainly due to the
reduced mortality achieved with effective antiretroviral therapies, calls for in-
creased rationality and awareness in health resources consumption also during
the early illness phases. Aim of this work is the estimation of the budget impact
related to the variation in backbone prescribing trends in naïve patients.
METHODS:Target population is the number of patients starting antiretroviral ther-
apy each year, according to the Italian HIV surveillance registry, excluding patients
receiving non-authorized or non-recommended regimens. We modeled 3-year
mortality and durability rates on a dynamic cohort, basing on international litera-
ture. Current Italian market shares of triple regimens containing first-choice back-
bones (TDF/FTC, ABC/3TC, TDF3TC, AZT/3TC) are compared to an hypothetical
scenario in which all patients eligible to ABC/3TC treatment (HLA-B*5701 negative
patients with 100,000 HIVRNA copies/mL) start a regimen containing this back-
bone as first line strategy. Annual cost for each regimen comprises drugs acquisi-
tion under hospital pricing rules, and monitoring exams and preventive tests, val-
ued basing on regional reimbursement tariffs. RESULTS: According to current
prescribing trends, in the next three years about 13,000 patients starting HIV ther-
apy will receive TDF/FTC (83% of the target population), and minor portions other
regimens (9% ABC/3TC, 8% AZT/3TC). Patients that would be eligible to ABC/3TC are
about six thousand more than those presently treated with this backbone, leading
to a saving of 3.1 million Euro over the three-year period. Sensitivity analyses on
different hypotheses of “third” drug market shares indicate savings ranging from
720 thousand to 3.9 million Euro. Most of this amount is due to reduced acquisition
costs and, secondarily, to lower monitoring needs. CONCLUSIONS: Where patient
features don’t force the choice of the backbone, ABC/3TC prescription may induce
substantial savings, allowing the release of resources needed to manage more
complicated/advanced cases.
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OBJECTIVES: To determine the economic impact of three different hospital-ac-
quired infections (HAI) in mechanically ventilated (MV) patients in intensive care
unit (ICU) and assess the attributable costs, hospital length of stay (LOS) and inpa-
tient mortality in a U.S. hospital database. METHODS: A U.S. retrospective cohort
study was undertaken using hospital database from the Premier Perspective of
adults (18 years old) with a stay  48h in 2007. Three HAIs were followed: blood-
stream infection (BSI), surgical site infection (SSI), and hospital-acquired pneumo-
nia (HAP) including ventilator-associated pneumonia (VAP). From a previous anal-
ysis, MV device was identified as an impactful risk factor in ICU showing higher
prevalence for HAP/VAP and BSI. Case subjects were defined as patients with HAI
event among the MV population. Economic criteria were defined as hospital LOS,
inpatient mortality and inpatient costs. RESULTS: Out of 463,491 patients meeting
the entry criteria, 101,540 (21.9%) received a MV setting. Focusing on this MV pop-
ulation, 51,683 (50.9%) patients developed HAI: HAP/VAP: 33.2%, BSI: 29.4%, and SSI:
2.3%. Compared with control, patients with HAI were more elderly (54% vs. 49%),
were more likely to be admitted via emergency room (86% vs. 78%), presented with
more severe illnesses, higher risk of mortality, and with central catheter place-
ments (67% vs. 39%). The inpatient mortality rate and mean LOS were higher in
patients with HAI (32% vs. 18% and 21.222.3 vs. 11.811.4 days, respectively).
Mean total costs were higher in HAI patients (56,751US$) compared to non-HAI
patients (34,032US$). In MV population, HAI patients had higher consumptions of
inpatient resources and inpatient mortality: extended LOS equal to 9.4 days, in-
creased total inpatient costs equal to 22,719US$ and extended mortality of 14%.
CONCLUSIONS: These data illustrate the significant economic burden and mortal-
ity of HAI in a category of at-risk population on MV and request the needs for
intervention.
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Pneumococcal diseases (PD), such as bacteremia, meningitis and pneumonia, are
associated with substantial burden in adults (50 years). Moreover, adults with
underlying chronic conditions (i.e., vascular, metabolic, or respiratory diseases)
have shown to have 3–6 times higher risk of PD compared with their healthy
controls. These people at higher risk will likely benefit most of PCV13 vaccination in
the new adult indication. OBJECTIVES: To estimate the expected 5-year economic
impact of targeted PCV13 vaccination compared to no vaccination in Finnish adults
(50 years) at higher risk for PD. METHODS: A budget impact model applying a
modified Markov-type structure was developed to predict the impact of PCV13
vaccination in terms of costs and PD events avoided. The model was built as a
dynamic open-cohort model to allow the annual evolution of the size of prevalent
target population with considered PCV13 indications. The results of model were
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extrapolated for the years 2012-2016 by applying population forecasts from the
official Finnish statistics. Health care resource use and Finnish unit costs (€2011,
societal perspective) were obtained from published national sources. RESULTS:
Approximately 35% of the 2.2 million Finns of over 50 years of age can be consid-
ered to be at moderate or high risk for PDs due to the underlying chronic medical
conditions. The vaccination of these people with PCV13 could provide an estimated
net budget savings of about €218 million compared to the current no-vaccination
situation during the five years. Among the risk groups considered, the largest net
savings (€66.2 million) could be expected to be obtained by vaccinating people with
heart disease due to its high prevalence in the target population. CONCLUSIONS:
The immunization of adults (50 years) at higher PD-risk with PCV13 vaccine will
potentially lead to substantial cost savings during the forthcoming years in Fin-
land.
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OBJECTIVES: To estimate the budget impact associated with use of Atazanavir as
1st line treatment in Spanish market of antiretroviral drugs for VIH patients, on
stable and sever health state. METHODS: An economic Model was developed to
evaluate the Budget Impact of using Atazanavir (ATV), as 1st line treatment, for VIH
patients in the Spanish National Health System perspective, over a 10-year period.
Therapies included in the analysis were Darunavir (DRV), Lopinavir (LPV) and Efa-
virenz (EFV). Patient data were obtained through microsimulation model, with a
patient cohort simulated, statistically significant and representative (N 40,000).
The costs were obtained from local databases and were considered pharmaceutical
and direct health care costs. An annual discount rate assumed was of 3%.The
discontinuation rates after AEs assumed for all treatments were: 71.3% from diar-
rhea, 61.3% from nausea, 28.8% from jaundice, 82.5% from rash and 55% from CNS
events. The results of BIM per patient were presented at annual and cumulative
level. RESULTS: Atazanavir use led to differential annual costs per patient after 10
years of treatment of 595€, 209€ and 76€, with respect to DRV, LPV and EFV. The
highest savings generated by ATV derived from durable health of 1st line treatment
(807€ DRV, 909€ LPV and 1045€ EFV), followed by return to health and durable viral
suppression. This savings offset ATV drug cost versus other antiretroviral drugs.
CONCLUSIONS: This analysis showed that treatment with Atazanavir for VIH pa-
tients, on stable and sever health state, generates net savings for Spanish National
Health System: 595€, 209€ and 76€, with respect to DRV, LPV and EFV, in terms of
differential annual costs per patient after 10 years treatment.
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OBJECTIVES: Recently, 13-valent Pneumococcal Conjugate Vaccine (PCV13) has
been approved for adults 50 years of age and older for the prevention of invasive
pneumococcal disease (IPD) caused by the vaccine serotypes. This study was aimed
to assess the clinical and economic impact of PCV13 use in adults with immuno-
compromising conditions based on HIV published data. METHODS: A budget im-
pact model for the whole HIV population was designed under the Spanish National
Health System with a 4-year time horizon. Calculations of cases were based on the
published IPD incidence (0.74%) and recurrent IPD ratio in this population. From
total IPD cases, 92% were considered bacteraemia originating from pneumonia,
5.5% bacteraemia without apparent focus and endocarditis and 2.5% meningitis.
PCV13 efficacy, serotype coverage, IPD mortality and disease related costs were
based on published data. Model was built up assuming full vaccination coverage
and no indirect effect. All costs were expressed in €2012. RESULTS: There would be
2,392 IPD cases in Spanish HIV patients over 4-year time horizon (598 annual cases).
The model predicts that the implementation of a PCV13 vaccination program for
HIV population would be a cost saving measure due to IPD cases averted. Over the
study period, PCV13 would prevent 646 IPD cases and 162 related deaths.
CONCLUSIONS:Based on this health economic evaluation, the inclusion of a PCV13
vaccination program for HIV population would be an efficient measure. PCV13
vaccination would have a high impact on pneumococcal disease prevention, avoid-
ing deaths and saving costs.
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OBJECTIVES: Separation of sick dairy cows to hospital pens, isolated from healthy
cows, is frequently used to manage risks of inadvertently meat and milk residue
violations associated with use of certain antimicrobials. However, drawbacks of
hospital pen moves are frequently overlooked.Our objective was to develop a
model 1) to quantify health and economic burden associated with hospital pen
moves, and 2) to compare the economic impact associated with choice of antimi-
crobials requiring a hospital pen move because of milk withholding (standard:
ampicillin, penicillin, oxytetracycline) to those not requiring milk withholding
(comparator: three ceftiofurs) and therefore avoiding hospital pen moves.
METHODS: A decision tree was developed in MS Excel to 1) estimate the impact of
hospital pen moves by considering extra labor, stress-induced reduction in milk
yield and immunity, risk of secondary diseases and associated treatment/culling/
replacement costs, and 2) compare standard and comparator treatments by con-
sidering treatment duration, milk withholding-associated revenue losses (based
on product labels) and impact of hospital pen moves. Costs and prices ($US, 2010:
producer’s perspective), risk data, and labor data were derived from published
sources. RESULTS: The economic burden of a hospital pen stay of 5 days was
estimated at $111.85/cow, mainly attributable to risk and costs of secondary dis-
eases. Ceftiofur prices ($29.33 to $107.99/cow) were generally higher than standard
antibiotics ($2.00 to $30.95/cow). However, incremental net income with ceftiofurs
compared to standard antibiotics ranged from $85.81 to $208.21/cow, the result of
withholding-associated reduced saleable milk ($51.00 to $71.40/cow) and addi-
tional costs of hospital pen moves ($111.85 to $156.34/cow) with standard
treatment. CONCLUSIONS: Compared to therapeutic treatments requiring milk
withholding and a hospital pen move, ceftiofurs’ higher prices were more than
offset by higher returns resulting from increased saleable milk and no additional
costs associated with hospital pen moves, and overall resulted in higher net in-
come for producers.
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OBJECTIVES: Antimicrobial resistance is a growing problem associated with many
bacterial infections. The problem of resistance is related to the use of antibiotics.
There is a causal relationship between antibiotic use and resistance which results
in decreased antibiotic effectiveness. Antimicrobial resistance varies among hos-
pitals significantly and results in a different financial burden due to cost-drivers
related to treatment failure including all medication costs, increased length of
hospital stay and additional medical resource consumption. Our objective was to
estimate the real life effectiveness of using different antibiotics in a certain hospi-
tal by analyzing the total cost of therapy during hospitalization. METHODS: A
cost-offset model was developed to support the individual therapeutic decisions of
hospitals. We analyzed a 6 months time period and a number of 59 complicated
intra-abdominal infection (IAI) episodes in a Hungarian county hospital retrospec-
tively. Based on the first antibiotic choice we defined different treatment pathways
to compare the length of stay and the total cost of the hospitalization in each
treatment arm. RESULTS: The average length of stay (LOS) with complicated IAI
was 5 days and increased to 8.6 days due to any adverse events. If the first antibiotic
treatment was not effective - means that the patient had to switched to another
antibiotic drug - the average LOS increased to 9.5 days. The cost difference of the
different antibiotic drugs ranged from 121% to 391% compared to the cheapest
treatment. The total hospitalization cost in case of the most expensive antibiotic
treatment was higher by an average of 8% compared to the total cost of the cheap-
est antibiotic drug treatment. CONCLUSIONS: In long term the impact of resis-
tance, the choice of adequate antibiotic therapy, the infection-control and the need
for real-life effectiveness analysis because of budgetary reasons are increasingly
important for hospitals.
PIN27
COST ANALYSIS OF VORICONAZOLE VERSUS LIPOSOMAL AMPHOTERICIN B
FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HEMATOLOGIC
PATIENTS IN GERMANY
Ostermann H1, Stephens J2, Gao X2, Weber B3, Charbonneau C4
1University Hospital Munich, Grosshadern, Munich, Germany, 2Pharmerit International,
Bethesda, MD, USA, 3Pfizer, Berlin, Germany, 4Pfizer, Paris, France
OBJECTIVES: We performed an economic evaluation of voriconazole vs liposomal
amphotericin B as first-line antifungals for invasive aspergillosis (IA) among pa-
tients with prolonged neutropenia or undergoing bone marrow or hematopoietic
stem-cell transplantation from a German hospital perspective. METHODS: A deci-
sion analytic model was constructed to estimate potential treatment costs of vori-
conazole vs liposomal amphotericin B. Each pathway was defined by probabilities
of an event and costs of clinical outcomes. Probabilities and costs were derived
from literature, clinical trials, and expert panels. In the base case, patients who
failed first-line therapy were assumed to experience a single switch between com-
parator drugs or add on the other drug as second-line treatment. Base-case evalu-
ation included drug management costs and additional hospitalization costs due to
severe adverse events. Sensitivity analyses were conducted to assess robustness of
results. All costs were inflated to 2011 Euros. RESULTS: Based on clinical trial suc-
cess rates of 52.8% (voriconazole) and 50% (liposomal amphotericin B), and length
of treatment (LOT)  10-day intravenous (IV)  5-day oral for voriconazole and
15-day IV for liposomal amphotericin B, voriconazole had a lower total treatment
cost than liposomal amphotericin B (€12,256 vs €18,133). Assuming the same effi-
cacy (50%) in first-line therapy, voriconazole still had a lower total treatment cost
than liposomal amphotericin B (€12,837 vs €18,133). Assuming the same LOT (10 or
15 days) in both arms, voriconazole maintained a lower cost. Cost savings were
primarily due to lower drug costs and shorter IV LOT associated with voriconazole.
The model was sensitive to drug prices and hospital per day costs. CONCLUSIONS:
This study suggests that voriconazole is likely to be cost-saving compared to lipo-
somal amphotericin B in the treatment of IA from the German hospital perspective.
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